Manchester Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Profit Growth -47.59%
- Net Worth -690.12%
- Total Assets 8496.80%
About Manchester Lifesciences
Manchester Lifesciences Private Limited (MLPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 18 November 2016 (Eight years and two months 27 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Integserve India Private Limited. The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Unmesh Jere, Pallayil Nair, Anil Kulku, and One other member serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24100MH2016PTC287765
-
Company No.
287765
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Nov 2016
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Manchester Lifesciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Unmesh Jere
|
Director | 23-Dec-2019 | Current |
|
Anil Kulku
|
Director | 15-Mar-2021 | Current |
|
Pallayil Nair
|
Director | 23-Dec-2019 | Current |
|
Keethol Soumya
|
Director | 22-Jun-2022 | Current |
Financial Performance of Manchester Lifesciences.
Manchester Lifesciences Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 47.59% decrease in profit. The company's net worth observed a substantial decline by a decrease of 690.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Manchester Lifesciences?
In 2017, Manchester Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Manchester Pharma Private LimitedUnmesh Jere is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Manchester Lifesciences?
Unlock and access historical data on people associated with Manchester Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Manchester Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Manchester Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.